Bob Kramer: Yeah. So it’s a really good question. As we have talked about, Boris, the transition that were, I will say in the fourth quarter of the executing in this transition started a number of years ago. The U.S. government has been procuring and placing into the Strategic National Stockpile, AV7909 all along the way. The transition will include as the product goes from basically a development stage product to an FDA licensed product that requires within the government to shift from BARDA to the strategic national stockpile in terms of who manages the overall procurement. In terms of the logistics, as we have talked about, the government’s strategy all along for many, many years has been to have enough anthrax vaccine in our country’s strategic national stockpile to protect 25 million lives with BioThrax, as you correctly say, which is a three-dose primary series that implied an inventory or a stockpile of 75 million doses for AV7909 given its two-dose nature that reduces the overall stockpile will come down to roughly 50 million doses.
As far as we know, the government is not — has not fully sourced either the 75 million or the 50 million dose level. So what we expect going forward is an annual procurement level to get them to — get to and maintain that 25 million lives protected level, which for AV7909 would be roughly 50 million doses.
Boris Peaker: Okay. Thank you for taking my questions.
Bob Kramer: Sure.
Operator: Thank you. And our next question comes from the line of Christopher Sakai with Singular Research. Your line is open. Please go ahead.
Unidentified Analyst: Hi. This is Asim for Chris. Firstly, I was wondering about NARCAN nasal spray to an extent you can share a little bit about the pricing strategy and potential cannibalization considering that you are expecting this to be contributing revenues in the second half of the year?
Bob Kramer: Yeah. Chris, thanks for joining the call. Thanks for the question. So as we have talked about, our focus right now kind of coming out of the AdCom meeting with the FDA and given the PDUFA date of March 29th, is to finalize discussions with the FDA regarding packaging and labeling, number one, as well as prepare our supply chain for launching the product in the summer of this year. It’s a little too early to really say with certainty what the pricing is going to be. Your question about cannibalization is interesting, because what we expect is that, when FDA approves and when we launch the product in the summer, there will be a bit of a transition period where you will likely see both the prescription branded product NARCAN, as well as the OTC distributed branded product in the market for a very short period of time and then when that’s over, it will be the OTC version of NARCAN in distribution.
So we don’t really — cannibalization may not be the what we expect going forward. Rather, as I said earlier, we expect to be able to kind of reenter or reestablish NARCAN in the retail space, where it was edged out because of generics while continuing to maintain a pretty healthy competitive position in the public interest market.
Unidentified Analyst: And in terms of the channels, you will be focusing on that depends on the label you will get or that is a little bit planned at this point?
Bob Kramer: So we are in active discussions with a number of the nation-wide pharmacy chains about distributing NARCAN in the retail space, as well as continuing to support the public interest market. So my comment around the label, Chris, it was really one of the areas of continued interest by the FDA is on the label and the packaging for NARCAN in the OTC setting. We have gotten good feedback coming out of the AdCom meeting with regard to that. So we would like to finalize that soon so we can finalize our supply chain solutions for planning for a launch in the summer.
Unidentified Analyst: We are expecting some comment based on your discussions, is FDA interested in or would like to have this product entirely over-the-counter maybe not immediately but long-term?
